The Growing Interest in Testosterone Therapy for Women During Menopause
When women face menopause, many seek ways to alleviate symptoms like low sexual desire and fatigue. One option that has been gaining attention is testosterone therapy. However, in the United States, this treatment remains complicated due to the lack of FDA-approved testosterone products specifically for women.
Recently, the Food and Drug Administration (FDA) held a public workshop aimed at discussing the safety, research gaps, and evidence regarding testosterone therapy for menopausal women. As more women look for solutions for their menopausal symptoms, the absence of approved treatments has led doctors to prescribe off-label options and custom formulations.
Dr. Kudzai Dombo, an experienced obstetrician-gynecologist based in Los Angeles, often sees this challenge in her practice. She explains that when patients are prescribed standard hormone treatments like estrogen and progesterone, one of the first questions they ask is about testosterone: “Do I need this?” While social media and peer recommendations may suggest a range of benefits, the current official guidelines back testosterone therapy primarily for one condition: hypoactive sexual desire disorder, or a persistent lack of sexual interest.
Despite the limited endorsed uses of testosterone, many women are interested in exploring its potential benefits for mood, energy, and overall quality of life. Unfortunately, the absence of products made specifically for women means that doctors often turn to male testosterone treatments, requiring careful adjustments for female patients.
The situation can be tricky. Without officially sanctioned options for women, patients often find themselves navigating through compounded creams or micro-dosing male gel packets, which can lead to further confusion regarding appropriate dosages.
Notably, because testosterone therapy for women is not officially recognized, insurance companies frequently deny coverage, adding further complications for both doctors and their patients. Dr. Dombo experienced this firsthand; when her own treatment was denied, she turned to compounded creams, but preferred to use the male gel packets instead.
“The irritation of this process shows how supportive our systems are not for women needing testosterone therapy,” Dombo remarked, sharing how she managed to find a cost-effective solution using a discount coupon for her male gel packets.
This complex landscape not only highlights the challenges in accessing care but also illustrates the broader issue of women’s health treatments. Dr. Dombo shares concerns about not having standardized methods for dosing male testosterone products, sometimes leading to ineffective treatments. In one instance, a patient who carefully measured her dosages for months saw no improvement in her hormone levels or symptoms.
The recent FDA meeting represents a crucial move forward for women’s health care. Advocates believe that continued pressure from patients and health professionals will encourage federal regulators to reassess access to testosterone therapy for women.
“I truly believe women deserve the same access to the treatments they need,” Dr. Dombo stated emphatically. She remains optimistic that regulatory changes will pave the way for safer and standardized options in hormone therapy.
“Sexual health contributes to overall well-being,” she concluded, emphasizing the importance of addressing these health needs comprehensively. As the conversation around women’s health evolves, so too does the hope for better solutions.
